COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
Onco-Innovations announces manufacturing of nanoparticle formulation by Dalton Pharma Services to advance preclinical studies, enhancing clinical readiness in cancer research -
COMMUNIQUÉ DE PRESSE
RE Royalties Announces Cancellation of Previously Announced Non-Brokered Listed Issuer Financing Equity Offering Due to Early Repayment from Clients
RE Royalties cancels private placement offering due to early loan repayments and share price volatility. Company well-capitalized for new opportunities and meeting bond maturity -
-
COMMUNIQUÉ DE PRESSE
Rapport Financier Semestriel 30 juin 2025
-
COMMUNIQUÉ DE PRESSE
GENFIT annonce l'arrêt de son programme VS-01 dans l'ACLF – le développement de VS-01 est recentré sur l'UCD
GENFIT annonce l'arrêt de son programme VS-01 dans l'ACLF et se recentre sur l'UCD pour traiter les troubles du cycle de l'urée. L'arrêt fait suite à un événement indésirable grave dans l'essai clinique UNVEIL-IT® -
COMMUNIQUÉ DE PRESSE
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
GENFIT discontinues VS-01 program in ACLF and shifts focus to UCD due to safety concerns. The company aims to accelerate other assets in ACLF, while exploring CCA data and reducing operating expenses -
-
COMMUNIQUÉ DE PRESSE
aap confirms Rubino Di Girolamo as CEO through the end of 2028; COO Agnieszka Mierzejewska will leave the company at the end of the year
CEO Rubino Di Girolamo extends contract at aap Implantate AG until 2028; COO Agnieszka Mierzejewska to leave in 2025. Company focuses on new antibacterial technology and strategic realignment
